CN1820618A - Health preserving liver protection tea and its preparing method - Google Patents

Health preserving liver protection tea and its preparing method Download PDF

Info

Publication number
CN1820618A
CN1820618A CN 200610066319 CN200610066319A CN1820618A CN 1820618 A CN1820618 A CN 1820618A CN 200610066319 CN200610066319 CN 200610066319 CN 200610066319 A CN200610066319 A CN 200610066319A CN 1820618 A CN1820618 A CN 1820618A
Authority
CN
Grant status
Application
Patent type
Prior art keywords
weight
parts
liver
tea
minutes
Prior art date
Application number
CN 200610066319
Other languages
Chinese (zh)
Other versions
CN100544605C (en )
Inventor
王晓
Original Assignee
王晓
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Abstract

The present invention relates to health preserving and liver protecting tea and its preparation process. The health preserving and liver protecting tea is prepared with nine kinds of Chinese medicinal materials, including gynostemma pentaphylla, haw, wolfberry fruit, red sage, fleeceflower root, etc in certain weight proportion, and through water decoction or alcohol extraction, mixing, drying, frying, bagging, Co-60 irradiation and other steps. The medicinal tea contains rich nutrients, and animal experiment and practical application proves its functions of preventing and treating chemical liver damage, raising bodyí»s immunity and helping treatment of fatty liver and no toxic side effect.

Description

养生护肝茶及其制备方法 Liver health tea and its preparation method

技术领域 FIELD

本发明涉及一种养生护肝茶及其制备方法,具体的说是一种以中草药为原料的中药茶及其制备方法,属于中药养生技术领域。 The present invention relates to a method for preparing health and Liver tea, specifically a method for preparing herbal tea herbal medicines and raw materials, belonging to the technical field of traditional Chinese medicine and health.

背景技术 Background technique

肝脏是人体最大的实质性消化器官,将各种营养物质转变成具有生物活性的蛋白质、脂类和糖原,从而保障了人体各个器官,尤其是心、脑、肾等脏器的功能活动,拥有健康的肝脏,就会拥有健康的身体。 The liver is the body's largest digestive substance, to convert various nutrients into a protein, lipid and glycogen biological activity, in order to protect the various organs of the body, especially the heart, brain, kidney and other organs of the functional activities, have a healthy liver, it will have a healthy body.

近年来由于生活水平的提高,饮食结构变化及预防保健措施相对滞后。 In recent years, due to the improvement of living standards, changes in diet and preventive health measures is lagging behind. 中国又是具有悠久的酒文化历史,而在这个大的环境背景下,使得热情好客的中国人大都具有饮酒的习惯,在推杯换盏间,难免会有饮酒过量的时候,而每一次饮酒,损伤最大的就是肝脏了。 China is wine culture has a long history, and in this great environment background, making the hospitality of the Chinese National People's Congress have drinking habits among Tuibeihuanzhan, it is inevitable there will be excessive drinking of time, and each time drinking , damage to the liver is the largest. 有记载说人大醉一次就等于得了一次肝炎,而且现在由酒而引起的肝损伤是逐年增多,而又由于肝损伤所引发的其他相关慢性疾病及导致自身免疫能力低下就更多了。 There are records that people got drunk once is equivalent to a hepatitis, and now liver damage caused by the wine is increasing year by year, but due to other diseases related to chronic liver injury caused by their immunity is low and lead to even more.

另一方面社会环境的变化,带来新的合成药剂及化学药品的增加,患者长期用药,服药,一旦药物有毒副作用,这种毒副作用只能依赖人体的肝脏来缓解,若患者本已体质虚弱、肝功能不健全,如此一来,更是恶性循环,这就和酒精中毒一样,是产生化学性肝损伤的又一原因。 On the other hand changes in the social environment, lead to increased new synthetic drug and chemicals, long-term medication of patients, medication, once the drug toxic side effects, such side effects can only rely on the body's liver to relieve, if the patient is already weak constitution , liver function is not perfect, this way, it is a vicious cycle, and which, like alcoholism, is another cause of chemical liver injury. 此外,由于工业的快速发展、人口增多,蔬菜水果等饮食品的需求量逐年增大,大部分种植者在种植的过程中使用化肥农药,由于农药残留等问题导致毒性物质在人体内的蓄积也是损伤肝脏的一大主要因素。 In addition, due to the rapid industrial development, population increase, demand for food products such as fruits and vegetables increased every year, most growers use chemical fertilizers and pesticides during cultivation, since pesticide residues and other issues leads to accumulation of toxic substances in the human body is one of the main factors that damage the liver.

由于生活节奏的日益加快,工作压力过大,生活不规律使得大部分人群处于亚健康状态,人们的免疫力低下是许多病发病的根本。 Due to the ever-accelerating pace of life, work pressure, irregular life makes the most of the population in a healthy condition, many people with low immunity disease incidence is fundamental.

治疗化学性肝损伤的药物中西药占绝大部分,西药均有毒副作用,也为疾病的治疗带来新的困难。 Chemical treatment of drug-induced liver injury accounted for most Chinese and Western medicine, Western medicine have toxic side effects, it also brings new difficulties for the treatment of diseases. 而目前用于化学性肝损伤的中药大部分性寒,通过降肝火来达到治疗肝损伤的目的,这种药物不能适用于多元化的肝损伤,且治疗效果不理想,并不能起到预防化学性肝损伤的作用。 The currently used chemical liver injury in most cold medicine, through livers to achieve the purpose of treatment of liver injury, the drug can not be applied to a wide range of liver injury, and treatment is not satisfactory, and can not play a preventive chemical the role of liver injury.

因此,人们对于能够预防及治疗化学性肝损伤,同时又能够提高人体免疫力,并且无毒副作用的中草药物养生调理有很大需求。 Therefore, people can prevent and treat chemical liver injury, but also can improve human immunity, and the toxic side effects of Chinese herbal medicine conditioning regimen in great demand.

现有药物大多为片剂,胶囊剂居多,人们工作繁忙不能做到定时服用也会影响疗效,本发明的另一特点是把本发明中草药物做成传统的药茶剂型饮用,人人每天都需要喝茶,服用方便,吸收迅速,适用于快节奏、高效率的工作学习和中国人的生活习惯。 Most existing drugs are tablets, capsules mostly busy people do not also affect the timing of taking effect, another feature of the present invention is that the herbal composition of the present invention made of conventional dosage forms herbal tea drinking day everyone need to drink tea, easy to take, rapidly absorbed, it is suitable for fast-paced, high-efficiency work, study and Chinese people's living habits.

目前国内在养生护肝茶的研制开发当中还是一个空白,没有一个疗效稳定,见效快、口感好服用方便、又没有副作用的药食两用茶。 Currently in research and development Hugan health tea which is still a blank, there is no effect of a stable, effective, convenient and good taste to take, and no side effects of medicinal and edible tea.

发明内容 SUMMARY

综上所述,人们对疗效稳定、无毒副作用、服用方便的养生护肝药茶仍存在很大需求。 In summary, the people of efficacy and stability, non-toxic side effects, easy to take the herbal liver health is still great demand. 本发明人经过反复研究,并通过临床实验和动物试验的反复验证,终于找到了有更好疗效并且服用方便、口感好的养生护肝茶,从而完成了本发明。 The present inventors have repeated studies, and through repeated verification of clinical trials and animal experiments, finally found a better efficacy and easy to take, taste good liver health tea, and completed the present invention.

本发明的目的是提供一种养生护肝茶。 Object of the present invention is to provide a liver health tea.

本发明的另一目的是提供该养生护肝茶的制备方法。 Another object of the present invention to provide a method for preparing the health tea liver.

本发明的技术方案是发明人基于祖国传统医学对肝脏保护的认识和养护原则,参考现代药理研究成就,经过反复验证筛选得出的。 Aspect of the present invention is a human invention is based on knowledge and principles of conservation of traditional medicine on the liver protection, refer to modern pharmacological research achievements, obtained after repeated verification screening. 本发明选择绞股蓝、山楂、枸杞子、丹参、何首乌、灵芝、葛根、陈皮和蒲公英进行组合,并配合本发明所述各原料重量配比使得各药物功效产生协同作用,从而能够有效的起到增强机体免疫力和调理化学性干损伤的作用。 The present invention selects Gynostemma, hawthorn, medlar, Salvia miltiorrhiza, Polygonum, Ganoderma lucidum, Pueraria, orange peel and dandelions combination, and with the present invention, the raw materials such that the weight ratio of each drug efficacy synergistic effect can be effectively enhanced play role of immunity and dry conditioning chemical injury.

其中选择绞股蓝是因为其含有绞股蓝皂甙、氨基酸、微量元素及多糖。 Wherein selecting Gynostemma because it contains Gypenosides, amino acids, trace elements and polysaccharides. 味苦、性寒,归心、肝、肾经。 Bitter, cold, heart, liver, kidney. 其具有降血压、降血脂、防止细胞癌化、增强机体免疫力和抗衰老等功效。 With lowering blood pressure, lowering blood pressure, preventing the cancerous cell, enhance immunity and anti-aging effects.

山楂味酸、甘,性温,归脾、胃、肝经,其主要含有黄酮类化合物槲皮素、槲皮甙、金丝桃甙、矢东菊素、儿茶精等,以及有机酸山楂酸、柠檬酸、苹果酸、枸橼酸、绿原酸、齐墩果酸、熊果酸等,具有消食化积,活血散瘀的作用。 Hawthorn Pickle, sweet, warm, spleen, stomach, liver, which mainly contain flavonoids quercetin, quercetin glycosides, hyperoside, eastern daisy vector element, catechin and the like, and organic acids hawthorn acid, citric acid, malic acid, citric acid, chlorogenic acid, oleanolic acid, ursolic acid, etc., with digestion of the plot, the effect of blood stasis.

枸杞子含有甜菜碱、芸香甙、β-D-葡萄糖甙、玉蜀黍黄素、酸浆果红素,还含有多种维生素、氨基酸及微量钙、磷、铁等。 Wolfberry betaine, rutin, β-D- glucoside, zeaxanthine, Physalis red pigment further contains vitamins, amino acids and trace amounts of calcium, phosphorus, iron and the like. 其味甘,性平。 Its sweet nature. 归肝、肾经。 The liver and kidney. 具有滋肾益精、养肝明目等功效。 Kidney having essence, nourishing eyesight and other effects.

丹参含有参酮I、IIA、IIIB,异丹参酮I、II,隐丹参酮,二氢异丹参酮等,还含有丹参素、原儿茶醛、维生素E、β-谷甾醇、羟基丹参酮IIA、丹参酸甲脂、次甲丹参醌、丹参新醌等。 Salvia contains one parameter I, IIA, IIIB, isobutyl tanshinone I, II, cryptotanshinone, dihydroisoquinoline tanshinone, further comprising Danshensu, protocatechuic aldehyde, vitamin E, β- sitosterol, hydroxy tanshinone IIA, methanesulfonic acid Salvia aliphatic, methine Salvia quinone, quinone new salvia. 其味苦、性微寒,归心肝经。 Its bitter, slightly cold, heartless by. 具有扩张冠状动脉,增加冠状动脉血流量,改善心肌功能,扩张外周血管,抑制血小板凝聚,对神经系统有镇静和安定作用。 With the expansion of the coronary artery, increasing coronary blood flow, improve cardiac function, peripheral vascular dilation, inhibit platelet aggregation, and have settled on the nervous system sedative effect.

何首乌含蒽醌类衍生物大黄酚、大黄素、大黄酸、大黄酚蒽酮及卵磷脂等,尚含芪类化合物2,3,5,4-四羟基对苯乙烯-2-O-β-D-葡萄糖干及没食子酸、淀粉、脂肪油、β-谷甾醇等。 Polygonum containing anthraquinone derivatives chrysophanol, emodin, rhein and chrysophanol anthrone lecithin, still containing a stilbene compound 2,3,5,4- tetrahydroxy-styrene -2-O-β- dry D- glucose and gallic acid, starch, fatty oils, [beta] -sitosterol and the like. 其味苦、甘、涩,性微温,归肝、肾经。 Its bitter, sweet, astringent, slightly warm, the liver and kidney. 具有补益肝肾,滋养精血,润肠通便,解毒止痒的功效。 With replenishing liver and kidney, nourish the blood, laxative, detoxification antipruritic effect.

灵芝含灵芝多醣、多种氨基酸、多种生物硷(如r-叁甲胺基丁酸等)、麦角甾醇、香豆精、有机酸、维生素等。 Containing Ganoderma lucidum polysaccharides, amino acids, alkaloids (e.g., methylamine r- three butyric acid), ergosterol, coumarin, organic acids, vitamins and the like. 性甘、味淡、微苦,平。 Gan, tasteless, bitter, flat. 归脾经、肺经、心经、肝经、肾经。 Owned spleen, lung, heart, liver, kidney. 灵芝药理作用有益气血,补精髓,养心安神,止咳平喘。 Ganoderma beneficial pharmacological effects blood, make up the essence, uneasiness of mind, cough and asthma.

葛根主要成分为异黄酮类化合物,内含大豆素、大豆甙、葛根素、还含有β-谷甾醇、羽扇烯酮、尿囊素、廿二烷酸、花生酸和多量淀粉。 Pueraria main components of isoflavones, containing daidzein, daidzin, puerarin, further containing β- sitosterol, lupine ketene, allantoin, docosanoic acid, arachidic acid and large amounts of starch. 其味甘、辛,性平。 Its sweet, octyl, flat. 归脾、胃经。 The spleen and stomach. 其具有解肌退热,透疹,生津止渴,升阳止泻之功效。 It has Jieji fever, rash, thirst, Sun diarrhea effect.

陈皮为芸香科植物橘的果皮。 Citrus Rutaceae orange peel. 含橙皮甙、川陈皮素、柠檬烯、a-蒎烯、B-蒎烯、B-水芹烯等。 Containing hesperidin, nobiletin, limonene, pinene A-, B- pinene, B- phellandrene like. 性味:性温,味苦、辛。 Taste: warm, bitter, acrid. 功能主治:理气健脾,燥湿化痰。 Indications: spleen qi, phlegm dampness. 用于胸脘胀满、食少吐泻、咳嗽多痰。 A chest abdominal fullness, eat less vomiting and diarrhea, cough.

蒲公英主要含有蒲公英甾醇、胆碱、菊糖和果胶等。 Dandelion mainly containing taraxasterol, choline, inulin and pectin. 其水提物对金黄色葡萄球菌、溶血性链球菌有抑制作用,对肺炎球菌、脑膜炎球菌、溶血性链球菌等也有一定抑制作用。 A water extract of Staphylococcus aureus, hemolytic streptococcus inhibition of pneumococcal, meningococcal, hemolytic streptococcus, also have some inhibitory effect. 其味苦、甘,性寒。 Its bitter, sweet, cold. 归肝、胃经。 Liver and stomach. 具有清热解毒,清利湿热等功效。 It has the effect of detoxification, clearing heat and so on.

上述9味药进行组合,增强人体免疫力,调理各种化学性肝损伤效果最佳,且本发明药物组分的用量也是经过发明人长期大量摸索总结得出的,各组分用量在下述重量范围内都具有很好的疗效并且无任何毒副作用。 9 herbs above combination, enhance immunity, various conditioning best chemical liver injury, and the amount of the pharmaceutical composition of the present invention the inventors also after long-term heavy explored and summed obtained, the components in the following amounts by weight the range has good results and without any side effects.

为实现本发明的目的,提出以下具体技术方案:一种养生护肝茶,它是由下述重量配比的原料制成:绞股蓝15~25重量份 山楂9~16重量份 枸杞子11~16重量份丹参6~10重量份 何首乌6~10重量份 灵芝7~15重量份葛根5~12重量份 陈皮3~9重量份 蒲公英2~8重量份所述的一种养生护肝茶,其各原料的最佳重量配比是:绞股蓝15~20重量份 山楂12~16重量份 枸杞子12~16重量份丹参8~10重量份 何首乌8~10重量份 灵芝10~15重量份葛根8~10重量份 陈皮5~9重量份 蒲公英5~8重量份所述的一种养生护肝茶的制备方法,它包括下列步骤:(1)按所述重量配比称取绞股蓝、山楂、枸杞子、丹参、何首乌、灵芝、葛根、陈皮、蒲公英,备用;(2)将所述重量配比的山楂、枸杞子、丹参、何首乌、灵芝、葛根、陈皮、蒲公英加水煎 For purposes of this invention, the following specific technical solution: A Liver health tea, which is prepared from the following materials by weight ratio: 15 to 25 parts by weight of Gynostemma 9 to 16 parts by weight of hawthorn medlar 11 to 16 6 parts by weight to 10 parts by weight of Salvia Polygonum 6 parts by weight to 10 parts by weight of Ganoderma 7 to 15 parts by weight of 5 to 12 Pueraria dried orange peel 3 to 9 parts by weight of one kind dandelion Liver health tea 2 to 8 parts by weight of which each feedstock weight ratio is preferred: 15 to 20 parts by weight of Gynostemma 12 parts to 16 parts by weight of hawthorn medlar 12 to 16 parts by weight of Salvia 8 parts by weight to 10 parts by weight of Polygonum Ganoderma 8 to 10 10 to 15 8 to 10 wt Pueraria Liver health tea one kind of preparation 5 parts by weight to 9 parts by weight of Citrus 5-8 parts by weight of the dandelion, comprising the steps of: (1) the ratio by weight of said weighed Gynostemma, hawthorn, medlar, Salvia miltiorrhiza, Polygonum, Ganoderma lucidum, Pueraria, orange peel, dandelion, standby; (2) the proportion by weight of hawthorn, medlar, Salvia miltiorrhiza, Polygonum, Ganoderma lucidum, Pueraria, tangerine peel, add water to cook dandelion ,提取液浓缩到在60度时测得相对密度为1.09~1.2的浓缩液;(3)将所述重量配比的绞股蓝粉碎至50目细度的粗粉;(4)将浓缩液在保持36度温度时和绞股蓝粗粉混合均匀、炒拌75~95分钟,即制备成本发明的活性组分。 , The extract was concentrated to 60 degrees measured relative density of the concentrate was 1.09 to 1.2; (3) the proportion by weight of Gynostemma crushed to coarse powder fineness 50 mesh; (4) held in the concentrate when the temperature 36 degrees and Gynostemma mixed meal, saute 75 to 95 minutes, i.e., the preparation of the active ingredient of the invention.

所述的一种养生护肝茶的制备方法,其中步骤(2)中加水煎煮三次,第一次加水10倍量浸泡190分钟后,煎煮180分钟、第二次加水6倍量煎煮120分钟、第三次加水2倍量煎煮65分钟。 Liver health tea one kind of production method, wherein the step (2) in boiling water three times, 10 times after the first 190 minutes soaking in water, boiling for 180 minutes, adding a second quantity of boiling water 6 times 120 minutes, twice the amount of the third boiling water for 65 minutes.

所述的一种养生护肝茶的制备方法,其中将步骤(4)制得的活性组分装袋后在70℃~80℃的温度下干燥9~12小时,即制得茶剂。 Liver health tea one kind of production method, wherein in step (4) after the active ingredient prepared bagging dried at a temperature of 70 ℃ ~ 80 ℃ 9 to 12 hours, i.e. to prepare tea.

所述的一种养生护肝茶的制备方法,其中还可以将步骤(4)制得的活性组分装袋后用钴-60照射4个KGY,180分钟,即制得茶剂。 A method for preparing health tea of ​​the liver, which also may be the step (4) after bagging active ingredient prepared is irradiated with Co-60 4 KGY, 180 minutes, which was prepared tea.

所述的何首乌宜用制首乌,所述的陈皮即橘皮。 Radix Polygonum appropriate to the system, i.e., peel the orange peel.

上述本发明所述养生护肝茶活性组分的制备方法,是采用水提组合的方法,其是本发明的优选方法。 Of the present invention is the method for preparing health tea Liver active ingredient is a combination of water extraction method, which is a preferred method of the present invention. 还可以用醇提的方法进行制备,其中可采乙醇、异丙醇、丙醇或丁醇等醇类,但乙醇提取效果最佳。 It may also be prepared by the method of alcohol extraction, wherein the recoverable ethanol, isopropanol, butanol, propanol or the like alcohol, but the best ethanol extract. 用具体方法如下:(1)按本发明所述重量配比称取各原料绞股蓝、山楂、枸杞子、丹参、何首乌、灵芝、葛根、陈皮、蒲公英,备用;(2)除绞股蓝外将各原料药用体积比为50%-90%的乙醇浸泡24小时后放入回流装置中乙醇回流提取三次,第一次用8倍量乙醇回流2小时、第二次用6倍量乙醇回流1.5小时、第三次用4倍量乙醇回流1小时;(3)回收提取液并通过120目不锈钢筛网过滤;(4)将过筛后的提取液在45~50℃下干燥,得到干浸膏;(5)将干浸膏与所述重量配比的绞股蓝混合均匀,即制成了本发明的活性组分。 By the following specific methods: (1) according to the present invention, the weight ratio of each raw material was weighed Gynostemma, hawthorn, medlar, Salvia miltiorrhiza, Polygonum, Ganoderma lucidum, Pueraria, orange peel, dandelion, standby; (2) except that each material Gynostemma medicinal volume ratio of 50% to 90% ethanol at reflux into the apparatus ethanol extracted three times soaked for 24 hours, refluxed for 2 hours with the first 8-fold amount of ethanol, a second time with 6-fold amount of ethanol was refluxed for 1.5 hours. 4 times with a third amount of ethanol was refluxed for one hour; and (3) recovering extracts were filtered through a 120 mesh stainless steel mesh; (4) extract was sieved and dried at 45 ~ 50 ℃, to obtain a dry extract; (5) the dry extract mixed with Jiaogulan weight ratio of the uniform, i.e., the active ingredient is made according to the present invention.

将上述活性组分干燥装袋,即制成了茶剂成品。 The above drying bagging active ingredient, i.e., the tea made from the finished product.

上述乙醇或水与药物的添加倍量关系为乙醇或水与药物的重量之比。 Ethanol or water with the above-described drug-fold amount added of the relationship of the weight ratio of alcohol or water to the drug.

本发明所提供的一种养生护肝茶,所用原料按所述重量份比,并按常规中成药剂的制备方法制成各种剂型,如茶剂、丸剂、口服液、滴丸剂等,但是这些并不用于限制本发明的保护范围,其中茶剂为本发明优选剂型。 The present invention provides a health tea liver, the parts by weight ratio of the raw material by using, a conventional method of preparation prepared in accordance medicine agents in various dosage forms, such as tea, pills, oral solution, pills and the like, but these are not intended to limit the scope of the present invention, wherein the present invention is preferably a dosage form tea.

服用方法:6g/次,一日三次,沸水冲泡饮用即可。 Dosage: 6g / times, three times a day, boiling water to drink.

本发明一个重要特点是药剂中含有丰富的营养成分,其中含有多种皂甙、有机酸、氨基葡萄糖以及多糖类。 An important feature of the present invention is an agent rich in nutrients, which contains various saponins, organic acids, polysaccharides, and glucosamine. 仅绞股蓝一项就含有80种皂甙。 Gynostemma to contain only 80 kinds of one saponin. 这种营养成分对调理各类化学性肝损伤以及提高机体免疫力都有较好的作用,且无毒副作用,适合长期服用。 Such nutrients for conditioning a variety of chemical-induced liver injury and improve immunity has a good effect, and toxic side effects for long-term use.

本发明茶剂中各营养成份含量见表1:表1 Tea present invention, the content of each of the nutritional components shown in Table 1: Table 1

另外本发明所述的养生护肝茶中还含有维生素C、维生素E、维生素B6、钙、磷、铁、锌以及叶酸等多种微量元素。 Further according to the present invention, liver health tea also contains trace elements vitamin C, vitamin E, vitamin B6, calcium, phosphorus, iron, zinc, and folic acid. 这些维生素是机体修复细胞的辅基,可以保护肝细胞和提高机体免疫力。 These vitamins are the body's repair prosthetic group of cells, can protect the liver cells and improve immunity. 本发明维生素及微量元素含量见表2:表2 The content of vitamins and trace elements according to the present invention are shown in Table 2: Table 2

通过以下动物实验验证本发明所述养生护肝茶具有调理和预防化学性肝损伤的功效。 Animal experiments by the present invention having a health tea liver conditioning and prevention of liver injury chemical effect.

(一)实验动物:北京大学医学部实验动物科学部[许可证号:SCXK-(京)2002-0001]繁殖的18~22g昆明种健康清洁级雄性小鼠。 (A) Experimental animals: animal experiments Peking University Health Science [License No: SCXK- (Beijing) 2002-0001] 18 ~ 22g Kunming healthy and clean male mice bred.

(二)仪器与试剂:解剖器械、灌胃针、AE100电子天平(96009)、755型分光光度计(2002001)、生理盐水、2M磷酸盐缓冲液(pH7.4) (Ii) Instrument and Reagents: dissecting instrument, gavage needle, the AE100 electronic balance (96009), 755 spectrophotometer (2,002,001), physiological saline, 2M phosphate buffer (pH7.4)

四氯化碳(CCl4),郑州化学试剂二厂生产,批号980906。 Carbon tetrachloride (CCl4 -), Zhengzhou Chemical Reagent Factory, batch number 980906.

丙二醛试剂盒 南京建成生物工程研究所批号:20040404谷胱甘肽试剂盒 南京建成生物工程研究所批号:20050615甘油三酯试剂盒 中生北控生物科技股份有限公司批号:220501(三)实验方法:建立损伤模后,各组进行肝组织中丙二醛、还原型谷胱甘肽和甘油三酯的测定,比较疗效。 MDA kit Nanjing Jiancheng Institute of Biotechnology batch number: 20040404 glutathione kit Nanjing Jiancheng Institute of Biotechnology batch number: 20050615 triglyceride kit BIOSINO Biological Technology Co., lot number: 220 501 (c) test method: after establishing mold damage, liver tissue were in each group of malondialdehyde, reduced glutathione and triglycerides, more efficacy.

(四)造模成功标准:模型对照组与空白对照组比较肝组织中丙二醛、还原型谷胱甘肽和/或甘油三酯含量显著升高(P<0.01)说明模型建立成功。 (Iv) modeling success criteria: the model control group and blank control group hepatic malondialdehyde, reduced glutathione and / or triglyceride levels were significantly increased (P <0.01) model successfully described.

(五)效果评判标准:在模型建立成功基础上,肝脏中丙二醛含量明显低于模型对照组、且差异具有显著性(P<0.05),即可判定该项指标结果阳性;还原型谷胱甘肽含量显著高于模型对照组,且差异具有显著性(P<0.05),即可判定该项指标结果阳性;甘油三酯明显低于模型对照组、且差异具有显著性(P<0.05),即可判定该项指标结果阳性;三项检测指标中任意两项指标阳性,即可判定本发明药茶具有治疗及预防化学性肝损伤的功效。 (E) Effect criteria: on the basis of the successful establishment of the model, MDA content in the liver was significantly lower than the model group, and the difference was significant (P <0.05), the index determination to a positive result; Reduced Valley glutathione were significantly higher than the model group, and the difference was significant (P <0.05), the index determination to a positive result; triglycerides were significantly lower than the model group, and the difference was significant (P <0.05 ), a positive result can be determined that the indicators; any two positive indicators detected three indicators, the present invention can be determined with herbal treatment and prevention of liver injury chemical effect.

实验例11、分组:将60只小鼠分为6组,分别为:本发明成人剂量(每日12克)的5倍、10倍、30倍即低、中、高剂量组,空白对照组、模型对照组1和模型对照组2。 Experimental Example 11, group: 60 mice were divided into 6 groups, namely: the present invention, the adult dose (12 grams per day) of 5-fold, 10-fold, 30-fold i.e. low, medium and high dose groups, blank control group model control group 1 and control group 2 model.

2、实验过程:将本发明药物用水配制,每日一次经口给予,连续灌胃45天,灌胃体积为0.2ml/10g鼠重,空白对照组和模型对照组1、2均用水代替本发明药物,每日灌胃体积与本发明药物组相同。 2. Experimental procedure: The pharmaceutical formulations of the present invention with water, once daily administered orally, intragastrically 45 days, intragastric volume of 0.2ml / 10g weight of mice, model control group and the control group was replaced by water of the present 1,2 drug discovery, fed daily volume of the pharmaceutical component of the present invention is the same. 给予结束后,将模型对照组1一次性灌胃给予50%乙醇12ml/kgBW,模型对照组2按0.2ml/10g体重皮下注射40%四氯化碳橄榄油溶液,空白对照组给予无菌水。 After the completion of the administration, the model control group 1 50% ethanol-time oral administration of 12ml / kgBW, model control group 2 Press 0.2ml / 10g of body weight subcutaneously injected 40% olive oil solution of carbon tetrachloride, the blank control group was given sterile water . 各组动物隔夜禁食16小时后处死,进行各项指标检测。 Groups of animals were sacrificed 16 hours after fasting overnight, the indicators for detection.

3、动物实验结果判定:表3本发明药茶对肝组织中丙二醛含量的影响 3, results of animal experiments determined: TABLE 3 Effect of herbal tea of ​​the present invention on the liver of malondialdehyde content

*:与模型对照组比较有显著差异性由表3可见,模型对照组1、2与空白对照组比较丙二醛含量显著升高(P<0.01),说明肝损伤模型建立成功。 *: Comparison with the model group have a significant difference can be seen from Table 3, Comparative MDA content model control group and the control group 1 were significantly higher (P <0.01), hepatic injury model successfully described. 中剂量组和高剂量组与模型对照组1、2比较,肝组织中丙二醛含量显著降低(P<0.05),结果阳性。 Middle dose group and high dose group and the model control group 1 compared liver malondialdehyde was significantly decreased (P <0.05), a positive result.

表4本发明药茶对肝组织中甘油三酯含量的影响 Table 4 Effect of herbal invention liver tissue triglyceride content of

*:与模型对照组比较有显著差异性由表4可见,模型对照组1、2与空白对照组比较甘油三酯含量显著升高(P<0.01),说明肝损伤模型建立成功。 *: Comparison with the model group have a significant difference can be seen from Table 4, the model group and the blank control group 2 triglyceride levels increased significantly (P <0.01), hepatic injury model successfully described. 中剂量组和高剂量组与模型对照组1、2比较,肝组织中甘油三酯含量显著降低(P<0.05),结果阳性。 Middle dose group and high dose group and the model control group 1 compared liver triglyceride content was significantly decreased (P <0.05), a positive result.

表5本发明药物对肝组织中还原型谷胱甘肽含量的影响 Table 5 Effect of the drug on liver tissue invention glutathione content

*:与模型对照组比较有显著差异性由表4可见,模型对照组1、2与空白对照组比较还原型谷胱甘肽含量显著降低(P<0.01),说明肝损伤模型建立成功。 *: Comparison with the model group have a significant difference can be seen from Table 4, the model group and the blank control group 1 reduced glutathione were significantly decreased (P <0.01), hepatic injury model successfully described. 中剂量组和高剂量组与模型对照组1、2比较,肝组织中还原型谷胱甘肽含量显著升高(P<0.05),结果阳性。 Middle dose group and high dose group and the model control group 1 compared liver glutathione were significantly increased (P <0.05), a positive result.

总之,模型对照组1、2与空白对照组比较丙二醛含量、还原型谷胱甘肽含量和甘油三酯含量均显著升高,说明模型建立成功。 In short, compare the content of MDA model group and control group 1, 2, reduced glutathione content and triglyceride levels were significantly increased, indicating a successful model. 经口给予小鼠不同剂量的本发明药物45天,与模型对照组1(酒精肝损伤模型)及模型对照组2(四氯化碳损伤模型)相比较,丙二醛含量明显低于模型对照组1、2,且差异具有显著性(P<0.05),可判定该项指标结果阳性;还原型谷胱甘肽含量显著高于模型对照组1、2,且差异具有显著性(P<0.05),可判定该项指标结果阳性;甘油三酯明显低于模型对照组1、2,且差异具有显著性(P<0.05),可判定该项指标结果阳性;三项检测指标均为阳性,可判定本发明药物具有预防化学性肝损伤的功效。 Mice were given different doses of oral drug of the present invention is 45 days, with the control group 1 (alcoholic liver injury model) and the model control group 2 (carbon tetrachloride injury model) is compared, MDA significantly lower than control groups 1, 2, and the difference was significant (P <0.05), the positive result can be determined that the indicators; glutathione were significantly higher than model group 2, and the difference was significant (P <0.05 ), a positive result can be determined that the indicators; triglycerides were significantly lower than the model group 2, and the difference was significant (P <0.05), the positive result can be determined that the indicators; three were positive indicators detected, the present invention may determine the drug has the effect of preventing chemical liver injury.

实验例21、分组:将50只小鼠分为5组,分别为:正常对照组、本发明药物人体剂量的5倍、10倍、30倍即低、中、高剂量组,模型对照组。 Experimental Example 21, groups: 50 mice were divided into five groups, namely: normal control group, 5 times the human dose of the medicament of the present invention, 10-fold, 30-fold i.e. low, medium and high dose groups and model control group.

2、动物造模:除正常对照组外,将其余各小鼠按0.2ml/10g体重皮下注射40%CCl4橄榄油溶液,每周两次,共6周。 2, Animal modeling: Except the normal control group, the remaining mice were 0.2ml / 10g of body weight subcutaneously injected 40% CCl4 olive oil solution, twice a week for 6 weeks. 6周后,一次性灌胃给予50%乙醇12ml/kgBW,灌胃体积为0.1ml/10g鼠重,正常对照组用水代替乙醇。 After 6 weeks, one-time oral administration of 50% ethanol 12ml / kgBW, intragastric volume of 0.1ml / 10g weight of mice, the normal control group with water instead of ethanol.

3、分组和给药:将除正常对照组外的其余各鼠随机分为4组,分别为低、中、高剂量组和模型对照组,正常对照组和模型对照组以无菌水5ml/kg灌胃,低、中、高剂量组以5ml/kg灌胃本发明药物,每周2次共6周,6周后各组动物隔夜禁食16小时后处死,进行各项指标检测。 3, and the administration group: each of the remaining mice in addition to the normal control group were randomly divided into 4 groups, respectively low, medium and high dose groups and model control group, model control group and normal control group sterile water 5ml / kg orally, low, medium and high dose groups at 5ml / kg orally medicament of the present invention, two times a week for 6 weeks, 6 weeks the animals in each group were sacrificed 16 hours after fasting overnight, the indicators for detection.

4、动物实验结果判定:表6本发明药物对肝组织中丙二醛含量的影响 4, results of animal experiments determined: TABLE 6 Effect of the drug on the invention MDA content in the liver tissue

*:与模型对照组比较有显著差异性由表3可见,模型对照组与正常对照组比较丙二醛含量显著升高(P<0.01),说明肝损伤模型建立成功。 *: Comparison with the model group have a significant difference can be seen from Table 3, Comparative MDA content model control group and normal control group were significantly higher (P <0.01), hepatic injury model successfully described. 中剂量组和高剂量组与模型对照组比较,肝组织中丙二醛含量显著降低(P<0.05),且接近正常值,可判定结果阳性。 Middle dose group and high dose group and model group, the content of malonaldehyde in liver tissue was significantly decreased (P <0.05), and close to normal, the determination result may be positive.

表7本发明药物对肝组织中甘油三酯含量的影响 Table 7 Effect of Drug invention liver tissue triglyceride content of

*:与模型对照组比较有显著差异性由表7可见,模型对照组与空白对照组比较甘油三酯含量显著升高(P<0.01),说明肝损伤模型建立成功。 *: Comparison with the model group have a significant difference can be seen from Table 7, the model control group and the control group significantly increased triglyceride levels (P <0.01), hepatic injury model successfully described. 高剂量组与模型对照组比较,肝组织中甘油三酯含量显著降低(P<0.05),且接近正常值,结果阳性。 High dose group and the model control group, the liver triglyceride content was significantly decreased (P <0.05), and close to normal, positive results.

5、结果说明:模型对照组与空白对照组比较丙二醛含量和甘油三酯含量显著升高,说明模型建立成功。 5, results show: the model control group and blank control group MDA content and triglyceride levels were significantly increased, indicating a successful model. 经口给予小鼠不同剂量的本发明药物6周,与模型对照组相比较,丙二醛含量明显低于模型对照组,且差异具有显著性(P<0.05)可判定该项指标结果阳性;甘油三酯明显低于模型对照组、且差异具有显著性(P<0.05),可判定该项指标结果阳性:三项检测指标中两项均为阳性,且高剂量组的丙二醛和甘油三脂的含量值与正常值相近,可判定本发明药物具有治疗化学性肝损伤的功效。 Mice were given different doses of oral drug of the present invention, six weeks, compared with the model control group, MDA content significantly lower than the control group, and the difference was significant (P <0.05) positive result may determine the index; triglycerides were significantly lower than the model group, and the difference was significant (P <0.05), it can be determined that a positive result indicator: three two were positive indicators detected, MDA and high-dose group and glycerin fat content with a normal value three similar, may determine the efficacy of therapeutic drug of the present invention has a chemical liver injury.

CCl4对肝毒性损伤是由于CCl4经肝细胞微粒体内细胞色素P450代谢成三氯甲基自由基,并在其启动的过氧化连锁反应中,产生毒性作用更强的超氧阴离子和氢氧离子,这些自由基通过脂质过氧化作用损伤肝细胞。 CCl4 toxicity on liver injury due to CCl4 hepatic microsomal cytochrome P450 cells in vivo metabolism to cellular trichloromethyl radical, and it starts a chain reaction of peroxide, the more toxic effects of superoxide anion and hydroxyl ions, these lipid peroxidation by free radical damage hepatocytes. 脂质过氧化反应也可直接或通过醛的过氧化产物作用于贮脂细胞,或通过激活枯否细胞释放细胞因子如转化生长因子β1作用于贮脂细胞,增加胶原生成,最终导致肝纤维化。 Lipid peroxidation may be directly or through the product to the action of Ito by oxidation of aldehydes or cytokine release by activation of Kupffer cells such as transforming growth factor β1 acts on Ito, increased collagen production, ultimately leading to liver fibrosis . 本实验结果表明,大鼠经CCl4等复合因素刺激6周后,其肝组织丙二醛含量显著升高,甘油三酯含量显著升高。 The experimental results showed that rat CCl4 other complex factors that stimulate 6 weeks, MDA content in liver tissue significantly increased triglyceride content was significantly increased. MDA是脂质过氧化的主要降解产物,可严重损伤细胞膜的结构,导致肝细胞坏死。 MDA is a major degradation of lipid peroxidation products, it can seriously damage the structure of the cell membrane, resulting in necrosis of hepatocytes. 本发明药物能明显降低慢性肝损伤大鼠肝组织丙二醛含量和甘油三酯含量,提高肝组织活性,减少氧自由基生成和加快自由基的清除,从而减轻氧自由基对肝细胞的损伤。 Medicament of the present invention can significantly reduce chronic liver tissue MDA content and triglyceride content liver damage, liver tissue improved activity, reduce oxygen free radicals and radical scavenging accelerated, thereby reducing free radical damage to the liver cells . 本发明所述养生护肝茶的这种抗脂质过氧化作用可以起到抗慢性肝损伤的功效,同时对于肝损伤的治疗效果也是显著的。 Liver health tea of ​​the present invention the anti-lipid peroxidation that may function efficacy against chronic liver injury, liver injury while for therapeutic effect is remarkable.

实验例3通过以下动物实验证明本发明药物具有增强免疫力的功效,根据卫生部《保健食品检验与技术规范》(2003版)规定进行动物实验。 Experimental Example 3 by animal experiments show that the drug present invention has the effect of strengthening the immune system, animal experiments according to the Ministry of Health "health food inspection and technical specifications" (2003 edition).

1、样品:本发明药物成人口服推荐剂量为每日12克,成人按体重60kg计算,取出内容物进行实验。 1, Sample: adult oral recommended dose of the drug of the present invention is 12 g per day, calculated according to adult weight 60kg, the contents were taken for the experiment.

2、实验动物与分组:北京大学医学部实验动物科学部[许可证号:SCXK-(京)2002-0001]繁殖的18~22g昆明种健康清洁级雄性小鼠,共120只。 2, animals and groups: Laboratory Animal Science, Peking University Health Science [License No: SCXK- (Beijing) 2002-0001] 18 ~ 22g Kunming male mice were healthy and clean reproduction, total 120. 每组40只,分3组,免疫1组进行碳廓清实验;免疫2组进行脏体比值测定、小鼠腹腔巨噬细胞吞噬鸡红细胞试验、迟发性变态反应实验、半数溶血值(HC50)得测定和抗体生成细胞数的测定;免疫3组进行ConA诱导的小鼠淋巴细胞转化实验、NK细胞的活性检测。 40 per group, divided into 3 groups, one group immunized carbon clearance test; immunized group ratio was measured viscerosomatic, mouse peritoneal macrophages chicken red blood test, delayed type hypersensitivity experiments, total hemolytic (the HC50) antibody production and assay have measured the number of cells; ConA-induced for three groups of mice immunized lymphocyte transformation test, NK cell activity is detected.

3、剂量选择:根据本发明药物成人推荐口服剂量(每天12克)的5倍、10倍、30倍分为高、中、低剂量组,用水配制成所需浓度,对照组予以等体积蒸馏水,分别给予受试动物灌胃,每天灌胃1次,灌胃体积为0.2ml/10g·BW,连续45天。 3, dose selection: the recommended adult oral dose The pharmaceutical of the present invention (12 g per day) 5 times, 10 times, 30 times as high, medium, low dose, formulated with water to the desired concentration, the control group received an equal volume of distilled water , the test animals were given intragastric gavage once a day, orally volume of 0.2ml / 10g · BW, 45 consecutive days.

4、实验方法:(1)脏器/体重比值测定:称重后处死小鼠,取出脾脏和胸腺,在电子分析天平上称重,计算脏/体比值。 4. Experimental Method: (1) the organ / body weight ratio was measured: After weighing the mice were sacrificed, the thymus and the spleen was removed, weighed on an electronic analytical balance, calculated dirty / body weight ratio.

(2)迟发型变态反应(DTH)(足跖增厚法) (2) delayed type hypersensitivity (DTH) (plantar thickening method)

小鼠腹腔注射2%(v/v)SRBC(0.2ml/每鼠)致敏后4天,测量左后足跖厚度,然后再测量部位皮下注射2%(v/v)SRBC(20μl/每鼠),于注射后24小时测量左后足跖厚度,同一部位测量三次,取平均值。 Mice by intraperitoneal injection of 2% (v / v) SRBC (0.2ml / per mouse) four days after sensitization, the left hind paw thickness measured, then measurement site hypodermic 2% (v / v) SRBC (20μl / per rat), 24 hours after injection in the left hind paw thickness measured, the same portion was measured three times and averaged. 以前后足跖厚度差值(足跖肿胀度)来表示DTH程度。 After the difference in thickness before the paw (paw swelling) to indicate the degree of DTH.

(3)ConA诱导的小鼠淋巴细胞转化实验无菌取脾,置于盛有适量无菌Hank's液的小平皿中,制成细胞悬液,经200目筛网过滤。 (3) ConA induced lymphocyte transformation experiments spleen aseptically, placed in sterile Hank's filled with an appropriate amount of liquid is small plates, the cell suspension was filtered through a 200 mesh sieve. 用Hank's液洗3次,每次离心10分钟(1000rpm)。 Washed 3 times with Hank's solution, each centrifuged for 10 minutes (1000rpm). 然后将细胞悬浮于2ml完全培养基中,计数活细胞数,用RPMI640培养液调整细胞浓度为5×106个/ml,再将细胞悬液分两孔加入24孔培养基板中,每孔1ml,在其中一孔加50μl ConA液(相当于5μg/ml),另一孔作为对照,置5%二氧化碳,37℃培养72小时。 The cells were then resuspended in 2ml complete medium, counted number of live cells, the culture was adjusted with RPMI640 concentration of 5 × 106 cells / ml, and then added to the cell suspension in two 24-well culture board holes, each hole 1ml, in one well was added 50μl ConA solution (corresponding to 5μg / ml), another hole as control device 5% carbon dioxide culture 37 ℃ 72 hours. 培养结束前4小时,每孔轻轻吸去上清液0.7ml,加入不含小牛血清的RPMI640培养液,同时加入MTT(5mg/ml)50μl/孔,继续结束后,每孔加入1ml酸性异丙醇,吹打混匀,使紫色结晶完全溶解。 4 hours before the end of culture, each well 0.7ml supernatant was gently aspirated, the culture medium not containing fetal calf serum RPMI640 while adding MTT (5mg / ml) 50μl / hole, continue after the end of each well was added 1ml acid isopropanol, mixed by pipetting the purple crystals completely dissolved. 然后将此液体用酶标仪测定,波长570nm。 This liquid is then measured with a microplate reader, a wavelength of 570nm. 淋巴细胞的增殖能力用加ConA孔的光密度值减去不加ConA孔的光密度值表示。 Lymphocyte proliferation by subtracting the added value of the optical density ConA well bore without ConA represents optical density.

(4)抗体生成细胞检测(Jeme改良波片法)取羊血,用生理盐水洗涤3次,每次离心10分钟(200r/min),将积压SRBC用生理盐水配成2%(v/v)的细胞悬液,每鼠腹腔注射0.2mL。 (4) detection of antibody-producing cells (JEME modified wave plate method) sheep blood taken, washed three times with saline, centrifuged for 10 minutes each time (200r / min), the SRBC with saline backlog paired 2% (v / v ) of cell suspension per mouse by intraperitoneal injection of 0.2mL. 将免疫后4天的小鼠处死,取脾,轻轻撕碎,用Hanks液制成细胞悬液,200目过筛,洗涤、离心2次,最后将细胞悬浮于5mL Hanks液中。 The 4 days after immunization mice were killed, spleen, slightly torn, the cell suspension was made of Hanks' solution, 200 mesh sieve, washed twice by centrifugation, cells were suspended in 5 mL final Hanks solution. 将表层培养基加热熔解后与等量的pH7.4、2倍浓度的Hanks液混合,分装小试管,每管0.5mL,再向管内加入用SA液配制的10%SRBC 50μl(v/v)/20μl脾细胞悬液,迅速混匀后倾倒于已刷薄层琼脂糖的波片上,待琼脂糖凝固后将波片水平扣放在波片架上,放入二氧化碳培养箱中温浴1.5小时,然后用SA液稀释的补体(1∶10)加入到波片凹槽内,继续温浴1.5小时后计数溶血空斑数。 After the heat-melted surface layer of the medium mixed with an equal amount of pH7.4,2 fold concentration of Hanks' solution, dispensing a small test tube, 0.5 mL per tube, was added again tube SA was formulated with 10% SRBC 50μl (v / v ) / 20μl spleen cell suspension rapidly after mixing was poured onto a thin layer of agarose brushed wave plate, wave plate until the agarose solidified after fastening on the horizontal shelf-wave plate, into carbon dioxide incubator bath for 1.5 hours , followed by complement (1:10) was added to the diluted SA-wave plate recesses, after warm bath for 1.5 hour counting continues hemolytic plaque number.

(5)半数溶血值(HC50)的测定取羊血,用生理盐水洗涤3次,每只鼠腹腔注射2%(v/v,用生理盐水配制)压积SRBC 0.2mL进行免疫,5天后,摘除眼球取血于离心管内,放置约1小时,将凝固血与管壁剥离,使血清充分析出,2000rpm离心10分钟,收集血清。 (5) Measurement total hemolytic (the HC50) sheep blood is taken, washed 3 times with physiological saline, each mouse by intraperitoneal injection 2% (v / v, formulated with saline) packed SRBC 0.2mL immunization, 5 days, enucleated blood in the centrifuge tube, for about an hour, peeled off the wall and the coagulation of blood, serum sufficiently precipitate, centrifuged at 2000 rpm for 10 minutes and serum was collected. 用SA缓冲液将血清稀释为200倍,取1mL于试管内,依次加入10%(v/v,用SA缓冲液配制)压积SRBC 0.5mL,补体1mL(用SA缓冲液按1∶10稀释)。 SA buffer with 200 times diluted serum, 1mL taken in a test tube were added 10% (v / v, buffer formulated with SA) hematocrit SRBC 0.5mL, 1mL complement (SA buffer with diluted 1:10 ). 另设不加血清的对照管(以SA缓冲液代替)。 Sera without separate control tubes (to SA buffer instead). 置37℃水浴中保温30分钟后,冰浴终止反应。 Post 37 ℃ water bath for 30 minutes, the ice bath to terminate the reaction. 2000rpm离心10分钟,取上清1mL,加都氏试剂3mL,同时取10%(v/v,用SA缓冲液配制)压积SRBC 0.25mL,加都氏试剂至4mL于另一试管中,充分混合,放置10分钟后,于540nm处以对照管作空白,分别测定各管光密度值。 2000rpm rpm for 10 minutes, the supernatant 1mL, 3 mL Grignard reagent were added, while taking 10% (v / v, with the SA buffer solution) hematocrit SRBC 0.25mL, are added to 4mL's reagent in another test tube, mixed, allowed to stand for 10 minutes, to impose a 540nm as blank control tubes, each tube were measured optical density. 溶血素的量以半数溶血值(HC50)表示,按下式计算:半数溶血值(HC50)=样品光密度值/SRBC半数溶血时的光密度值×稀释倍数。 Hemolysin expressed as the amount of total hemolytic (HC50), calculated as follows: optical density × dilution factor of the total hemolytic (HC50) = optical density of the sample / SRBC hemolysin.

(6)小鼠碳廓清实验小鼠尾静脉注射以生理盐水稀释4倍的墨汁,每10g体重注射0.1mL,墨汁注入后立即计时,与注入墨汁后2、10分钟,分别以内眦静脉取血20μl,加入到2mLNa2CO3溶液中摇匀。 (6) Mouse carbon clearance test tail vein injection of saline diluted 4-fold in the ink, the timing immediately after the injection of 0.1 mL per 10g of body weight, the ink injection, the ink injection 2,10 minutes, respectively, within the angular vein blood 20μl, 2mLNa2CO3 solution was added to the shake. 以Na2CO3溶液作空白对照,用722型分光光度计在600nm波长处比色测光密度值(OD)。 In Na2CO3 solution as control, with 722-type spectrophotometer at a wavelength of 600nm colorimetric photometric density (OD). 将小鼠处死,取肝脾,称重,计算吞噬指数a。 The mice were killed, spleen, weighed to calculate the phagocytic index a.

(7)小鼠腹腔巨噬细胞吞噬鸡红细胞实验小鼠腹腔注射20%(v/v,用生理盐水配制)压积鸡红细胞(2000rpm,10min)悬液1mL,间隔30分钟,颈椎脱臼处死,取腹腔巨噬细胞洗液1mL,滴于载波片上,放入垫有湿纱布的搪瓷盒里,置37℃孵育箱温育30分钟。 (7) mouse peritoneal macrophage phagocytosis of chicken erythrocytes mice intraperitoneally 20% (v / v, formulated with saline) chicken red blood cell hematocrit (2000rpm, 10min) suspension 1mL, 30 minutes apart, killed by cervical dislocation, peritoneal macrophages wash 1mL, drops on the carrier sheet, placed in gauze pad wet enamel box, an incubator at 37 ℃ incubated for 30 minutes. 孵毕,于生理盐水中漂洗,以除去贴片细胞,晾干。 Bi hatch, rinsed in saline to remove cell patch, dry. 以甲醇∶丙醇(1∶1)固定,4%(v/v)Giemsa-磷酸缓冲液染色再用蒸馏水漂洗晾干。 Methanol: propanol (1/1) is fixed, 4% (v / v) Giemsa- phosphate staining buffer solution and then rinsed with distilled water to dry. 油镜下计数,每片计数100个巨噬细胞,按下式计算吞噬率和吞噬指数:吞噬率%=吞噬鸡红细胞的巨噬细胞数/计数的巨噬细胞数×100% Oil were counted, counting 100 sheets per macrophage, phagocytic index and phagocytic rate is calculated as follows:% phagocytosis = phagocytosis rate of number of macrophages chicken red blood / count number of macrophages × 100%

吞噬指数=被吞噬的鸡红细胞总数/计数的巨噬细胞数。 Phagocytic index = Total number of macrophages chicken red blood cells engulfed / count.

(8)NK细胞活性测定取传代后24小时生长良好的YAC-1细胞(存活率>95%)按1×106/mLYAC-1细胞悬液加3H-TdR10μlCi进行标记,于37℃5%二氧化碳培养箱中培养2小时,每30分钟震荡一次,标记后的细胞用培养液洗涤3次,重悬于培养液中,是细胞浓度为1×105个/mL。 24 hours Growth good YAC-1 cells (viability> 95%) by 1 × 106 / mLYAC-1 cell suspension was added 3H-TdR10μlCi labeled post (8) NK cell activity assay take passaged at 37 ℃ 5% CO culture incubator for 2 hours, once every 30 minutes shaking, the cells were labeled with the culture solution was washed three times, resuspended in culture medium to a cell concentration of 1 × 105 / mL. 受试小鼠颈椎脱臼处死,无菌取脾,制成脾细胞悬液,用Hanks洗涤3次,每次1000rpm10分钟,再用2mL含10%小牛血清的RPMI640完全培养基,用台酚兰染色计数(或细胞数应在95%以上),调整细胞浓度为1×107个/mL。 Tested mice were sacrificed by cervical dislocation, the spleens aseptically prepare a spleen cell suspension was washed 3 times with Hanks each 1000rpm10 minutes, then 2mL containing RPMI640 10% calf serum complete medium, with trypan blue staining count (or the number of cells should be more than 95%), adjust the cell concentration of 1 × 107 th / mL. 在96孔板中每孔加100μl标记的靶细胞,试验孔加100μl效应细胞,空白对照组孔加100μl培养基,最大稀放孔加100μlTritonX-100。 In 96 well plates each well 100μl labeled target cells, effector cells 100μl test well of blank control wells was added 100μl culture medium, the maximum discharge hole plus dilute 100μlTritonX-100. 每个样品设3个复孔,置5%二氧化碳,37℃培养4小时。 Each sample was provided three holes, set 5% CO 2, culture 37 ℃ 4 hours. 用多头细胞取集器取集于玻璃纤维滤纸上,用液闪仪测定每分钟脉冲数(cpm)NK细胞活性=(1-实验孔cpm/(空白对照孔cpm-最大释放孔cpm))×100%5、实验数据统计:用Excel/Spss软件进行统计学分析。 Take collector assembly with long cells take on a glass fiber filter paper, measuring the number of pulses per minute (cpm) NK cell activity with liquid scintillation counter = (1 - experimental wells cpm / (maximal release blank control wells cpm- hole cpm)) × 100% 5, the experimental data statistics: statistical analysis was performed using Excel / Spss software.

6、实验结果表8各组小鼠初始体重 6, the experimental results in Table 8 initial body weight of mice in each group

表9各组小鼠中期体重 Table 9 Body weight of mice in each interim

表10各组小鼠结束期体重 Table 10. End of body weight of mice in each group

表11各组小鼠体重增长 Table 11 Groups of mice of weight gain

由表8-11可见,各剂量组实验初、中、末期小鼠体重及实验期间小鼠体重增长对照相比,无显著性差异(P>0.05)。 Seen from Table 8-11, early experiments in each dose group, middle and end of mouse body weight and body weight gain during the experimental period compared to the control mice, no significant difference (P> 0.05).

表12本发明药物对小鼠免疫器官脏器/体重比值的影响 Table 12 Effect of the invention the pharmaceutical mice Immune Organ / body weight ratio

由表12可见,经口给予小鼠不同剂量的本发明药物45天,对小鼠脾脏/体重和胸腺/体重比值无显著影响(P>0.05)。 12 seen from the table, the mice orally administered with different doses of medicament of the present invention 45 days of mouse spleen and thymus weight / body weight ratio had no significant effect (P> 0.05) /.

表13本发明药物对小鼠迟发型变态反应(DTH)的影响(x±s) Table 13 Effect of the drug on mice invention delayed type hypersensitivity (DTH) to (x ± s)

*:与对照组比较有显著性由表13可知,经口给予小鼠不同剂量的本发明药物45天,剂量组小鼠足跖肿胀度与对照组比较有增高趋势,中、高剂量组与对照组比较,差异具有显著性(P<0.05)。 *: Compared with control group was significant apparent from Table 13, mice were orally administered various doses of a drug according to the present invention, 45 days, paw swelling dose group and the control group tended to increase the comparison, in high dose group and compared to a control group, the difference was significant (P <0.05).

表14本发明药物对小鼠淋巴细胞增殖能力实验的影响(x±s) Table 14 Drug invention on proliferation of mice with experimental lymphocytes (x ± s)

由表14可知,经口给予小鼠不同剂量的本发明药物45天,各剂量组对小鼠淋巴细胞转化能力有增高趋势,高剂量组与对照组比较,差异具有显著性(P<0.05)。 As apparent from Table 14, mice were orally administered various doses of a drug according to the present invention, 45 days, each dose group tended to increase the ability of mouse lymphocytes conversion, high-dose group and the control group, the difference was significant (P <0.05) .

表15本发明药物对小鼠抗体生成细胞数的影响 Table Effect of drug discovery to generate the number of cells on antibody 15

*:与对照组比较有显著性由表15可知,经口给予小鼠不同剂量的本发明药物45天,各剂量组小鼠抗体生成数与对照组比较有增高趋势,中、高剂量组与对照组比较差异具有显著性(P<0.05)。 *: Compared with control group was significant apparent from Table 15, mice were orally given different doses of the agents of the invention 45 days, the mouse antibody in each dose group and the control group number generation tended to increase, the high dose group and controls, the difference was significant (P <0.05).

表16本发明药物对小鼠半数溶血值(HC50)的影响 Table 16 Effect of the invention the pharmaceutical Mice total hemolytic (the HC50) of

*:与对照组比较有显著性由表16可知,经口给予小鼠不同剂量的本发明药物45天,各剂量组小鼠半数溶血值与对照组比较有增高趋势,中(P<0.05)、高剂量组(P<0.01)与对照组比较差异具有显著性。 *: Compared with control group was significant apparent from Table 16, mice were orally administered various doses of a drug according to the present invention, 45 days, half of the mice in each dose group and the control group hemolysis value tended to increase in (P <0.05) , high dose group (P <0.01) difference compared with the control group was significant.

表17本发明药物对小鼠单核-巨噬细胞碳廓清的影响 Table 17 agents of the invention on mouse monocyte - macrophage clearance of carbon

*:与对照组比较有显著性由表17可知,经口给予小鼠不同剂量的本发明药物45天,各剂量组小鼠吞噬指数与对照组比较有增高趋势,中、高剂量组小鼠吞噬指数与对照组比较差异具有显著性(P<0.01)。 *: Compared with control group was significant apparent from Table 17, mice were orally administered various doses of a drug according to the present invention, 45 days, phagocytic index in each dose group and the control group tended to increase in the high dose group phagocytic index difference compared with the control group was significant (P <0.01).

表18本发明药物对小鼠巨噬细胞吞噬鸡红细胞吞噬率的影响(x±s) Table 18 Effect of Drug invention phagocytic macrophage phagocytosis rate of chicken erythrocytes (x ± s)

表19本发明药物对小鼠巨噬细胞吞噬鸡红细胞吞噬指数的影响(x±s) Table 19 Effect of Drug invention phagocytic macrophage phagocytic index of chicken red blood cells (x ± s)

由表18、19可知,经口给予小鼠不同剂量的本发明药物45天,各剂量组小鼠巨噬细胞吞噬鸡红细胞能力未见明显影响(P>0.05)。 As apparent from Table 18 and 19, mice were given different doses of oral drug of the present invention is 45 days, each dose group mice macrophage phagocytic ability of chicken red blood cells were not significantly affected (P> 0.05).

表20本发明药物对小鼠NK细胞活性的影响 Table 20 Effect of the drug on the invention NK cell activity in mice

*:与对照组比较有显著性由表20可知,经口给予小鼠不同剂量的本发明药物45天,各剂量组小鼠NK细胞活性与对照组比较有增高趋势,中、高剂量组与对照组比较差异具有显著性(P<0.05)。 *: Comparison with control group has significantly apparent from Table 20, mice were given different doses of oral drug of the present invention is 45 days, NK cells activity of the control group of mice in each dose group compare tended to increase, the high dose group and controls, the difference was significant (P <0.05).

7、实验结果说明:经口给予小鼠低、中、高剂量本发明药物45天,能提高小鼠的迟发型变态反应、半数溶血值、抗体生成细胞数、单核-巨噬细胞碳廓清能力、ConA诱导的小鼠淋巴细胞转化能力及NK细胞的活性。 7, experimental results show that: the mice orally administered low, medium and high doses of the drug of the present invention is 45 days, the mice can be improved delayed type hypersensitivity, total hemolytic, antibody-producing cells, monocyte - macrophage carbon clearance capacity, ConA induced lymphocyte transformation and NK cell activity capacity. 对小鼠体重增长、胸腺体重比值、脾脏体重比值、小鼠巨噬细胞吞噬鸡红细胞的能力,均无明显影响。 Weight gain of the mice, the weight ratio of thymus, spleen weight ratio, the ability of chicken erythrocytes phagocytic macrophages, were not affected. 以上实验结果说明本发明所述养生护肝茶具有增强免疫力的功效。 The results above indicate liver health tea of ​​the present invention has the effect of strengthening the immune system.

实验例4本发明药物根据《保健食品检验与评价技术规范》(2003版)进行安全性毒理学试验,评价结果如下:1、急性经口LD50结果:对雌、雄小鼠的急性经口LD50均大于21500mg/kg·BW,属无毒物。 Experimental Example 4 Drug invention toxicological test according to "Health food inspection and evaluation of technical specifications" (2003 Edition), the evaluation results are as follows: 1, the results of the acute oral LD50: for female, male mice acute oral LD50 greater than 21500mg / kg · BW, is a non-toxic.

2、三项遗传毒性试验结果:三项遗传毒性试验(Ames试验、小鼠骨髓嗜多染红细胞微核试验、小鼠精子畸形试验)结果均为阴性。 2, three Genetic Toxicity Test Results: three genotoxicity tests (Ames test, mouse bone marrow micronucleus test, sperm abnormality test) were negative.

3、30天喂养结果:以成人推荐剂量(成人推荐剂量为每日12克)的5倍、10倍、30倍即低、中、高剂量的本发明药物给大鼠灌胃45天,试验期间,各剂量组大鼠体重增长、事务利用率与对照组比较无显著差异(P>0.05),雌、雄鼠血生化指标、血常规指标及肝/体、脾/体、肾/体、雄鼠睾/体比值与对照组比较均无显著性(P>0.05)。 3,30 day feeding Results: The recommended dose for adults (recommended adult dose of 12 g per day) of 5-fold, 10-fold, 30-fold i.e. low, medium and high doses of the drug to the present invention gavage to rats 45 days, the test during growth of rat body weight in each dose group, no significant difference (P> 0.05) Recovery and transaction control, female, male blood biochemical indexes, blood indices and liver / body, spleen / body, kidney / body, male testis / body weight ratio compared with control group there was no significant (P> 0.05). 肝、脾、肾、胃、十二指肠、睾丸(卵巢)组织病理检查无明显损害。 Pathological examination of liver, spleen, kidney, stomach, duodenum, testis (ovary) tissue without significant damage. 说明本发明药物45天喂养大鼠,各项指标观察未产生毒副作用。 DESCRIPTION The present invention is a pharmaceutical fed rats 45 days, the indicator does not produce toxic side effects were observed.

实验例5以下是本发明药物临床人体试食实验,说明本发明药物具有降血脂功效。 The following Experimental Example 5 of the present invention are pharmaceutical tasting human clinical experiments, the present invention is described with lipid-lowering efficacy of the drug.

1、高血脂的诊断标准:(1)血清总胆固醇TG>6.5毫摩尔/升;(2)甘油三脂TG>2.2毫摩尔/升;(3)低密度脂蛋白-胆固醇LDL-C>4.16毫摩尔/升;(4)高密度脂蛋白-胆固醇HDL-C<0.91毫摩尔/升;2、受试者纳入标准单纯血脂异常的人群,保持平常饮食,半年内采血2次,如果两次血清总胆固醇均为≥5.5mmol/L或甘油三脂≥1.8mmol/L者,其中18岁以下、65岁以上、妊娠或哺乳期妇女、合并有心肝肾和造血系统等严重原发性疾病、精神病患者、短期内服用于本发明药物功能有关的物品影响对结果判断者除外。 1, hyperlipidemia diagnostic criteria: (1) total serum cholesterol, TG> 6.5 mmol / l; (2) triglycerides TG> 2.2 mmol / l; (3) LDL - cholesterol, LDL-C> 4.16 mmol / l; (4) high-density lipoprotein - cholesterol, HDL-C <0.91 mmol / l; 2, dyslipidemia subject inclusion criteria pure population, maintain a normal diet, the blood 2 months, if the two serum total cholesterol are ≥5.5mmol / L or triglyceride ≥1.8mmol / L, of whom 18 years of age, over 65 years of age, pregnant or lactating women, combined determination of liver and kidney and hematopoietic system and other serious primary disease, psychiatric patients, short-term impact of a medicament for oral items related functions of the present invention except those determination results.

3、受试者分组:符合受试者纳入标准的100例血脂高受试者,随机分为本发明药物组和空白对照组: 3, packets subject: subjects meet the inclusion criteria were 100 cases of high blood subjects were randomized into drug group and the control group of the present invention:

本发明药物组:男性18例,女性32例,年龄最小35岁,最大64岁,平均49.50±7.41岁,平均病程3.21±2.79年。 The present invention is a pharmaceutical group: 18 males and 32 females, aged 35 years minimum, maximum of 64 years, mean 49.50 ± 7.41 years, the mean duration of 3.21 ± 2 79 years.

空白对照组:男性20例,女性30例,年龄最小36岁,最大65岁,平均50.50±9.28岁,平均病程3.50±2.60年。 Control group: 20 males, 30 females, the youngest 36 years old, maximum 65 years, mean 50.50 ± 9.28 years, mean duration of 3.50 ± 2 60 years.

4、服用方法:本发明药物组服用本发明茶剂,6克/次,每日口服3次,沸水冲泡饮用,连续45天。 4, taking the method: taking a pharmaceutical component of the present invention, the present invention tea, 6 g / time, 3 times a day orally, boiling water for drinking, 45 consecutive days. 空白对照组服用安慰剂,用量与次数与本发明药物组相同。 Placebo control group, and the number and amount of pharmaceutical present invention is the same.

5、效果评定标准:有效:血清总胆固醇(TC)降低>10%,甘油三脂(TG)降低>15%,高密度脂蛋白胆固醇(HDL-C)上升>0.104mmol/L。 5, the effect evaluation criteria: Effective: serum total cholesterol (TC) reduction> 10%, triglyceride (TG) reduced> 15%, high density lipoprotein cholesterol (HDL-C) increased> 0.104mmol / L.

无效:未达到有效标准者。 Invalid: does not meet the criteria were valid.

6、人体试食试验结果判定表21主要症状改善情况 6, human tasting test result determination Table 21. The main improvement of symptoms

()为空白对照组表22功效判定 () For the control group the efficacy of the table 22 is determined

组间比较*P<0.05总之,在45天中,本发明药物组的50例中,胆固醇平均下降0.98±0.89mmol/L,甘油三脂平均下降0.45±0.59mmol/L,其中有效42例,总有效率84.00%;空白对照组50例中,胆固醇平均下降0.08±0.43mmol/L,甘油三脂平均下降0.06±0.31mmol/L,其中有效3例,总有效率6.00%。 In between the two groups * P <0.05 In summary, 45 days, 50 cases of the present invention is a pharmaceutical group, average decrease cholesterol 0.98 ± 0.89mmol / L, triglycerides lowered average 0.45 ± 0.59mmol / L, wherein the effective 42 cases, the total efficiency of 84.00%; 50 cases in the control group, average decrease cholesterol 0.08 ± 0.43mmol / L, triglycerides lowered average 0.06 ± 0.31mmol / L, wherein the effective three cases, the total efficiency of 6.00%. 说明本发明药物具有降血脂的功效。 DESCRIPTION hypolipidemic drug of the present invention has the effect.

实验例6以下是本发明药物临床人体试食实验,说明本发明药物对化学性肝损伤有治疗功效。 Experimental Example 6 The following is a pharmaceutical tasting human clinical experiment of the present invention, the present invention has described the therapeutic efficacy of the pharmaceutical chemical liver injury.

1、肝功能诊断标准:(1)γ谷氨酰转肽酶(GGT):5~50IU(2)谷丙转氨酶(ALT):5~40IU(3)谷草转氨酶(AST):5~40IU2、受试者纳入标准单纯血脂异常的人群,保持平常饮食,半年内采血2次,如果两次采血肝功能指标不合格者,其中18岁以下、65岁以上、妊娠或哺乳期妇女、合并有心肝肾和造血系统等严重原发性疾病、精神病患者、短期内服用与本发明药物功能有关的物品影响对结果判断者除外。 1, liver diagnostic criteria: (1) γ-glutamyl endopeptidase (GGT): 5 ~ 50IU (2) alanine aminotransferase (ALT): 5 ~ 40IU (3) and aspartate aminotransferase (AST): 5 ~ 40IU2, inclusion criteria mere subjects of dyslipidemia population, maintain a normal diet, blood twice within six months, if the two blood liver function failure, of whom 18 years of age, over 65 years of age, pregnant or lactating women, associated with darling kidney and hematopoietic system and other serious primary disease, mental illness, drug-taking functions of the present invention affect the goods concerned, except for a short period determined by the result.

3、受试者分组:符合受试者纳入标准的100例受试者,随机分为本发明药物实验组和对照组:试食组:男性30例,女性20例,年龄最小33岁,最大62岁,平均47.50±6.78岁,平均病程6.21±2.18年。 3, packets subject: subjects meet the inclusion criteria 100 subjects were randomly divided into groups according to the present invention the pharmaceutical experimental and control groups: test group: 30 males, 20 females, aged 33 years minimum, maximum 62 years old, average 47.50 ± 6.78 years, mean duration of 6.21 ± 2. 18 years.

空白对照组:男性32例,女性18例,年龄最小32岁,最大61岁,平均46.50±7.16岁,平均病程6.50±2.03年。 Blank control group: 32 males and 18 females, aged 32 years minimum, maximum 61 years, mean 46.50 ± 7.16 years, the mean duration of 6.50 ± 2 03 years.

4、服用方法:本发明药物试食组服用本发明药物茶剂,6克/次,每日口服3次,沸水冲泡饮用,连续45天。 4. Use: Drug administration test group present invention is a pharmaceutical agent of the present invention, tea, 6 g / time, 3 times a day orally, boiling water for drinking, 45 consecutive days. 对照组服用进口利平脂,用量和次数与实验组相同。 The control group received Pingzhi inlet Lee, dosage and the number of the same experiment.

5、效果评定标准:有效:各项指标接近或达到正常值。 5, the effect evaluation criteria: Effective: the indicators approach or reach normal values.

无效:未达到有效标准者。 Invalid: does not meet the criteria were valid.

6、人体试食试验结果判定表23服用本发明药物前后血液中转氨酶含量的变化 6, human tasting test results determination table change transaminase levels in blood before and after administration of the present invention is a pharmaceutical 23

表23表明,治疗前两组的肝细胞损害程度基本相同,服用本发明药物的试食组,肝功能得到明显好转,而服用进口利平脂的对照组肝功能恢复不理想。 Table 23 shows that the extent of liver cell damage before treatment is substantially the same drugs test group of the present invention, the liver function was significantly improved, while taking advantage Pingzhi inlet control group of liver function recovery is not satisfactory.

表24功效判定 Table 24 Efficacy judgment

组间比较*P<0.05总之,在45天中,本发明药物试食组的50例中,其中有效48例,总有效率96.00%;对照组50例中,其中有效29例,总有效率58.00%。 Between the two groups * P <0.05 In summary, 45 days, 50 cases of drug test group of the present invention, wherein the effective 48 cases, the total efficiency of 96.00%; 50 cases in the control group, where the effective 29 cases, the total efficiency 58.00%. 说明本发明药物对肝功能恢复有很好的疗效。 Description inventive drug on liver function returned to have a good effect.

本发明的优点与有益效果:本发明药茶含有丰富的营养成分,其中含有多种皂甙、有机酸、氨基葡萄糖以及多糖类。 Advantages of the invention and advantages: the present invention herbal tea is rich in nutrients, which contains a variety of saponins, organic acids, polysaccharides, and glucosamine. 经动物实验及临床实验证明,具有治疗、调理及预防化学性肝损伤的功效,对于提高人体免疫力方面有显著效果,同时对脂肪肝具有辅助治疗作用,无任何毒副作用。 The animal experiments and clinical trials show that a therapeutic, conditioning and effectiveness of the prevention of chemical liver injury, have a significant effect in improving human immunity aspect, while the role of adjuvant therapy of fatty liver, without any side effects.

本发明药物作为茶剂饮用,其服用和携带方便、口感好。 Agents of the invention as a tea to drink, and take it easy to carry, good taste.

具体实施方式 detailed description

通过以下实施例来进一步阐述本发明药物及其制备方法,按以下配比制备的本发明所述的养生护肝药茶,通过临床实验验证,均可达到所述之功效。 Agents of the invention is further illustrated by the following preparation method and its embodiments, hepatoprotective herbal health according to the invention is prepared from the following ingredients, clinical experiments, can achieve the effect of the.

实施例1本发明药物茶剂制备(1)称取绞股蓝25g、山楂12g、枸杞子11g、丹参8g、何首乌8g、灵芝7g、葛根5g、陈皮5g、蒲公英2g,备用;(2)将所述重量配比的山楂、枸杞子、丹参、何首乌、灵芝、葛根、陈皮、蒲公英加水煎煮三次,第一次加水10倍量浸泡190分钟后,煎煮180分钟、第二次加水6倍量煎煮120分钟、第三次加水2倍量煎煮65分钟。 Preparation of tea medicament embodiment the invention one case (1) Weigh Gynostemma 25g, hawthorn 12g, medlar 11g, Salvia 8g, Polygonum 8g, Ganoderma 7g, Pueraria 5g, Citrus 5g, dandelion 2g, standby; (2) the the ratio by weight of hawthorn, medlar, Salvia miltiorrhiza, Polygonum, Ganoderma lucidum, Pueraria, tangerine peel, dandelion boiling water three times, 10 times after the first 190 minutes soaking in water, boiling for 180 minutes, the second water addition fried 6 times the amount of boiled for 120 minutes 2 times the amount of the third boiling water for 65 minutes. 提取液浓缩到在60度时测得相对密度为1.09~1.20的浓缩液;(3)将所述重量配比的绞股蓝粉碎至50目细度的粗粉;(4)将浓缩液在保持36度温度时和绞股蓝粗粉混合均匀、炒拌75分钟;(5)装袋,钴-60照射4个KGY,180分钟,即制得茶剂。 Extract was concentrated to 60 degrees when measured relative density of the concentrate was 1.09 to 1.20; (3) the proportion by weight of Gynostemma crushed to a coarse powder of 50 mesh fineness; (4) in the concentrate for 36 when the temperature of the mixed and Gynostemma meal, saute 75 minutes; (5) bagging, cobalt-60 irradiation 4 KGY, 180 minutes, that is to prepare tea.

实施例2(1)称取绞股蓝20g、山楂16g、枸杞子16g、丹参10g、何首乌10g、灵芝15g、葛根12g、陈皮9g、蒲公英8g,备用;(2)将所述重量配比的山楂、枸杞子、丹参、何首乌、灵芝、葛根、陈皮、蒲公英加水煎煮三次,第一次加水10倍量浸泡190分钟后,煎煮180分钟、第二次加水6倍量煎煮120分钟、第三次加水2倍量煎煮65分钟。 Example 2 (1) Weigh Gynostemma 20g, hawthorn 16g, medlar 16g, Salvia 10g, Polygonum 10g, Ganoderma lucidum 15g, Pueraria 12g, tangerine peel 9g, dandelion 8g, standby; (2) the weight ratio of hawthorn, medlar, Salvia miltiorrhiza, Polygonum, Ganoderma lucidum, Pueraria, tangerine peel, dandelion boiling water three times, 10 times after the first 190 minutes soaking in water, boiling for 180 minutes, the amount of second water boiling for 120 minutes 6 times, the third 2 times the amount of water addition boiling for 65 minutes. 提取液浓缩到按在60度时测得相对密度1.09~1.20的浓缩液;(3)将所述重量配比的绞股蓝粉碎至50目细度的粗粉;(4)将浓缩液在保持36度温度时和绞股蓝粗粉混合均匀、炒拌85分钟;(5)装袋后在70℃的温度下干燥9小时,即制得茶剂。 Extract was concentrated at 60 ° to press the relative density of the concentrate measured 1.09 to 1.20; pulverized to a fineness of 50 mesh (3) the weight ratio of Gynostemma meal; (4) in the concentrate for 36 when the temperature of the mixed and Gynostemma meal, saute 85 minutes; (5) at a bagging was dried at 70 ℃ 9 hours, i.e. to prepare tea.

实施例3(1)称取绞股蓝20g、山楂9g、枸杞子15g、丹参6g、何首乌6g、灵芝10g、葛根8g、陈皮5g、蒲公英3g,备用;(2)除绞股蓝外将各原料药用体积比为50%的乙醇浸泡24小时后放入回流装置中乙醇回流提取三次,第一次用8倍量乙醇回流2小时、第二次用6倍量乙醇回流1.5小时、第三次用4倍量乙醇回流1小时;(3)回收提取液并通过120目不锈钢筛网过滤;(4)将过筛后的提取液在45℃下干燥,得到干浸膏;(5)将干浸膏与所述重量配比的绞股蓝混合均匀,即制得活性组分;(6)将上述活性组分干燥装袋,即制成了茶剂成品。 Example 3 (1) Weigh Gynostemma 20g, hawthorn 9g, medlar 15g, Salvia 6g, Polygonum 6g, Ganoderma lucidum 10g, Pueraria 8g, Citrus 5g, dandelion 3g, standby; (2) the raw materials except the pharmaceutically acceptable Gynostemma Volume ratio of 50% ethanol after 24 hours of immersion into the recirculation device in ethanol extraction three times, first at reflux for 2 hours with 8 times the amount of ethanol and a second time with 6-fold amount of ethanol was refluxed for 1.5 hours, and the third with 4 the amount of ethanol was refluxed for one hour; and (3) recovering extracts were filtered through a 120 mesh stainless steel mesh; (4) extract was sieved and dried at 45 ℃, to obtain a dry extract; (5) and the dry extract the mixing ratio by weight of Gynostemma uniform, i.e., to prepare an active component; (6) the above dried bagging active ingredient, i.e., the tea made from the finished product.

实施例4本发明药物的颗粒剂制备(1)称取绞股蓝15g、山楂16g、枸杞子12g、丹参10g、何首乌10g、灵芝15g、葛根10g、陈皮3g、蒲公英8g,备用;(2)将所述重量配比的山楂、枸杞子、丹参、何首乌、灵芝、葛根、陈皮、蒲公英加水煎煮三次,第一次加水10倍量浸泡190分钟后,煎煮180分钟、第二次加水6倍量煎煮120分钟、第三次加水2倍量煎煮65分钟。 Preparation of granules Example medicament four invention (1) Weigh Gynostemma 15g, hawthorn 16g, medlar 12g, Salvia 10g, Polygonum 10g, Ganoderma lucidum 15g, Pueraria 10g, tangerine peel 3g, dandelion 8g, standby; (2) The said proportion by weight of hawthorn, medlar, Salvia miltiorrhiza, Polygonum, Ganoderma lucidum, Pueraria, tangerine peel, dandelion boiling water for three times, the first time plus 10 times the amount of water after 190 minutes soaking, boiling for 180 minutes, 6 times the amount of the second water addition boiling 120 minutes, twice the amount of the third boiling water for 65 minutes. 提取液浓缩到在60度时,测得相对密度为1.09~1.20的浓缩液;(3)将所述重量配比的绞股蓝粉碎至50目细度的粗粉;(4)将浓缩液在保持36度温度时和绞股蓝粗粉混合均匀、炒拌90分钟,即制得活性组分;(5)将活性组份加入乙醇做粘合剂,加入淀粉做填充剂,压制成颗粒剂。 Extract was concentrated to 60 degrees when measured relative density of the concentrate was 1.09 to 1.20; (3) the proportion by weight of Gynostemma crushed to a coarse powder of 50 mesh fineness; (4) held in the concentrate when the temperature 36 degrees and Gynostemma mixed meal, saute 90 minutes, i.e., to obtain the active component; (5) the active ingredient was added ethanol as a binder, filler starch is added and pressed into granules.

实施例5本发明药物丸剂的制备将本配方中主要活性组分制成丸状制剂,分为普通(大、小)丸状制剂和小滴丸制剂。 The main active ingredient in this formulation pelletized formulation divided into ordinary (large, small) and a small pellet formulation for preparing a pharmaceutical formulation Pill pills embodiment of the invention, five cases. 使用的粘合剂不同,可制成蜜丸、水丸、糊丸、蜡丸和浓缩丸等。 Using different binders, it can be made pill, pill, pill paste, pill wax pellet and the like.

(1)称取绞股蓝20g、山楂12g、枸杞子15g、丹参8g、何首乌6g、灵芝10g、葛根8g、陈皮5g、蒲公英5g,备用;(2)将所述重量配比的山楂、枸杞子、丹参、何首乌、灵芝、葛根、陈皮、蒲公英加水煎煮三次,第一次加水10倍量浸泡190分钟后,煎煮180分钟、第二次加水6倍量煎煮120分钟、第三次加水2倍量煎煮65分钟。 (1) Weigh Gynostemma 20g, hawthorn 12g, medlar 15g, Salvia 8g, Polygonum 6g, Ganoderma lucidum 10g, Pueraria 8g, Citrus 5g, dandelion 5g, standby; (2) the proportion by weight of hawthorn, medlar, Salvia miltiorrhiza, Polygonum, Ganoderma lucidum, Pueraria, tangerine peel, dandelion boiling water three times, 10 times after the first 190 minutes soaking in water, boiling for 180 minutes, the amount of second water 6 times 120 minutes of boiling, water was added 2 third times the amount of boiling for 65 minutes. 提取液浓缩到在60度时,测得相对密度为1.09~1.20的浓缩液;(3)将所述重量配比的绞股蓝粉碎至120目细度的粗粉;(4)将浓缩液和绞股蓝粗粉混合均匀、炒拌95分钟,即制得活性组分;(5)将活性组份加适合的粘合剂和辅料制成球形制剂。 Extract was concentrated to 60 degrees when measured relative density of the concentrate was 1.09 to 1.20; (3) the proportion by weight of Gynostemma crushed to coarse powder fineness of 120 mesh; (4) and the concentrate Gynostemma mixed meal, saute 95 minutes, i.e., to obtain the active component; (5) made into a spherical preparation of the active ingredient plus suitable binders and excipients.

Claims (6)

  1. 1.一种养生护肝茶,其特征在于,它是由下述重量配比的原料制成:绞股蓝15~25重量份 山楂9~16重量份 枸杞子11~16重量份丹参6~10重量份 何首乌6~10重量份 灵芝7~15重量份葛根5~12重量份 陈皮3~9重量份 蒲公英2~8重量份 A health tea Liver, characterized in that it is made of the following weight proportions of raw materials: 15 parts to 25 parts by weight of Gynostemma 9 to 16 parts by weight of hawthorn medlar 11 to 16 wt Salvia 6 to 10 wt. 6 to 10 parts by weight of Polygonum multiflorum Ganoderma 7 parts by weight of 5 to 15 parts by weight to 12 parts by Pueraria dried orange peel 3 to 9 wt dandelion 2 to 8 parts by weight
  2. 2.根据权利要求1所述的一种养生护肝茶,其特征在于,各原料的重量配比是:绞股蓝15~20重量份 山楂12~16重量份 枸杞子12~16重量份丹参8~10重量份 何首乌8~10重量份 灵芝10~15重量份葛根8~10重量份 陈皮5~9重量份 蒲公英5~8重量份 2. The liver health tea according to claim 1, wherein the weight ratio of each raw material is: Gynostemma 15 parts by weight to 20 parts by weight of hawthorn 12 to 16, 12 to 16 parts by weight of wolfberry Salvia 8 ~ 5 to 9 parts by weight 10 parts by weight of Polygonum 8 parts by weight to 10 parts by weight of Ganoderma 10 to 15 parts by weight of 8 to 10 Pueraria Citrus dandelion 5-8 parts by weight
  3. 3.据权利要求1或2所述的一种养生护肝茶的制备方法,其特征在于,它包括下列步骤:(1)按所述重量配比称取绞股蓝、山楂、枸杞子、丹参、何首乌、灵芝、葛根、陈皮、蒲公英,备用;(2)将所述重量配比的山楂、枸杞子、丹参、何首乌、灵芝、葛根、陈皮、蒲公英加水煎煮,提取液浓缩到在60度时测得相对密度为1.09~1.2的浓缩液;(3)将所述重量配比的绞股蓝粉碎至50目细度的粗粉;(4)将浓缩液在保持36度温度时和绞股蓝粗粉混合均匀、炒拌75~95分钟,即制备成本发明的活性组分。 A method of preparing tea or health of the liver 3. According to claim 1, characterized in that it comprises the following steps: (1) the ratio by weight of said weighed Gynostemma, hawthorn, medlar, Salvia, Polygonum, Ganoderma lucidum, Pueraria, orange peel, dandelion, standby; (2) the proportion by weight of hawthorn, medlar, Salvia miltiorrhiza, Polygonum, Ganoderma lucidum, Pueraria, tangerine peel, dandelion boiling water, the extract was concentrated at 60 degrees to the measured relative density of the concentrate was 1.09 to 1.2; (3) the proportion by weight of Gynostemma crushed to coarse powder fineness 50 mesh; (4) mixing coarse and Gynostemma 36 degrees while maintaining the liquid temperature and concentrated uniform, saute 75 to 95 minutes, i.e., the preparation of the active ingredient of the invention.
  4. 4.根据权利要求3所述的一种养生护肝茶的制备方法,其特征在于,所述的步骤(2)中加水煎煮三次,第一次加水10倍量浸泡190分钟后,煎煮180分钟、第二次加水6倍量煎煮120分钟、第三次加水2倍量煎煮65分钟。 4. A method of preparing liver health tea according to claim 3, wherein said step (2) in boiling water for three times, 10 times the amount of the first 190 minutes soaking in water, boiling 180 minutes, the amount of second water boiling for 120 minutes 6 times, 2 times the amount of the third boiling water for 65 minutes.
  5. 5.根据权利要求3所述的一种养生护肝茶的制备方法,其特征在于,将步骤(4)制得的活性组分装袋后在70℃~80℃的温度下干燥9~12小时,即制得茶剂。 5. A method for preparing a liver health tea according to claim 3, wherein, in step (4) after the active ingredient prepared bagging dried at a temperature of 70 ℃ ~ 80 ℃ 9-12 hours, i.e. to prepare tea.
  6. 6.根据权利要求3所述的一种养生护肝茶的制备方法,其特征在于,将步骤(4)制得的活性组分装袋后用钴-60照射4个KGY,180分钟,即制得茶剂。 6. A method for preparing a liver health tea according to claim 3, wherein, in step (4) is irradiated with Co-60 4 KGY active ingredient after bagging obtained, 180 min, i.e., prepared tea.
CN 200610066319 2006-03-28 2006-03-28 Health preserving liver protection tea and its preparing method CN100544605C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200610066319 CN100544605C (en) 2006-03-28 2006-03-28 Health preserving liver protection tea and its preparing method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200610066319 CN100544605C (en) 2006-03-28 2006-03-28 Health preserving liver protection tea and its preparing method

Publications (2)

Publication Number Publication Date
CN1820618A true true CN1820618A (en) 2006-08-23
CN100544605C CN100544605C (en) 2009-09-30

Family

ID=36922315

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200610066319 CN100544605C (en) 2006-03-28 2006-03-28 Health preserving liver protection tea and its preparing method

Country Status (1)

Country Link
CN (1) CN100544605C (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101664087B (en) 2009-08-31 2011-05-11 通化腾龙生物科技有限公司 Health-care liver benefiting tea
CN102265950A (en) * 2011-01-12 2011-12-07 余海生 The driver with meditation, eyesight, and fatigue Chufan tea manufacturing method thereof
CN102342351A (en) * 2011-09-07 2012-02-08 温州市天禾生物科技有限公司 Liver-protection tea
CN101803730B (en) 2009-11-12 2012-08-22 天津市百奥生物技术有限公司 Health care food with auxiliary protection role on chemical liver injury and preparation method thereof
CN102669667A (en) * 2012-05-25 2012-09-19 北京三奇本草医药技术有限公司 Health food with dual functions of protecting liver and adjusting blood fat and preparation method thereof
CN102688303A (en) * 2011-05-24 2012-09-26 郑彦 Health liver-protecting tea and making method thereof
CN103125937A (en) * 2013-02-04 2013-06-05 南京观海生医药科技有限公司 De-alcoholic liver protection agent and preparation method thereof
CN103652192A (en) * 2013-12-11 2014-03-26 山东中大药业有限公司 Liver protection tea
CN103689175A (en) * 2013-12-27 2014-04-02 陈洁 Liver and health protection tea
CN104782833A (en) * 2015-03-24 2015-07-22 张建迎 All-season health tea and preparation method thereof

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101664087B (en) 2009-08-31 2011-05-11 通化腾龙生物科技有限公司 Health-care liver benefiting tea
CN101803730B (en) 2009-11-12 2012-08-22 天津市百奥生物技术有限公司 Health care food with auxiliary protection role on chemical liver injury and preparation method thereof
CN102265950A (en) * 2011-01-12 2011-12-07 余海生 The driver with meditation, eyesight, and fatigue Chufan tea manufacturing method thereof
CN102265950B (en) 2011-01-12 2012-11-21 余海生 Mind-calming, eye-brightening, restlessness-removing and fatigue-resisting tea for drivers and preparation method thereof
CN102688303A (en) * 2011-05-24 2012-09-26 郑彦 Health liver-protecting tea and making method thereof
CN102688303B (en) 2011-05-24 2014-03-26 郑彦 Health liver-protecting tea and making method thereof
CN102342351A (en) * 2011-09-07 2012-02-08 温州市天禾生物科技有限公司 Liver-protection tea
CN102669667A (en) * 2012-05-25 2012-09-19 北京三奇本草医药技术有限公司 Health food with dual functions of protecting liver and adjusting blood fat and preparation method thereof
CN102669667B (en) 2012-05-25 2013-07-17 北京三奇本草医药技术有限公司 Health food with dual functions of protecting liver and adjusting blood fat and preparation method thereof
CN103125937A (en) * 2013-02-04 2013-06-05 南京观海生医药科技有限公司 De-alcoholic liver protection agent and preparation method thereof
CN103652192A (en) * 2013-12-11 2014-03-26 山东中大药业有限公司 Liver protection tea
CN103689175A (en) * 2013-12-27 2014-04-02 陈洁 Liver and health protection tea
CN104782833A (en) * 2015-03-24 2015-07-22 张建迎 All-season health tea and preparation method thereof

Also Published As

Publication number Publication date Type
CN100544605C (en) 2009-09-30 grant

Similar Documents

Publication Publication Date Title
CN1732916A (en) Compound medical health-caring preparation containing procyanidins and other functional ingredients
CN101721563A (en) Three high rehabilitation tea
CN1099992A (en) Nourishing tea
JP2003192605A (en) Lipase inhibitant
CN1457808A (en) Iron scale dendrobium compound preposition and preparation and use
Balch Prescription for herbal healing
CN1452875A (en) Health tea with rhodiola root and glossy ganoderma as main material and its making process
CN1520737A (en) Vitamin polysaccharide candy and its process
CN102100874A (en) Chinese patent drug for treating diabetes and preparation method thereof
US20030232099A1 (en) Health-care products and methods for preparing and using the same
CN1613383A (en) Green healthy beverage
CN101698028A (en) Fat-reducing and weight-losing composite and preparation method thereof
CN104757356A (en) Auxiliary blood sugar lowering composition, and preparation method, preparations and application thereof
CN102308988A (en) Dendrobium health product having function of human body immunization enhancement
CN102344876A (en) Nine-medicine Shengzi red fruit wine and preparation method thereof
CN102669667A (en) Health food with dual functions of protecting liver and adjusting blood fat and preparation method thereof
KR20120007275A (en) Composition comprising plants extract mixture for immune enhancement
CN1742980A (en) Chinese medicinal lotion for new-borne baby&#39;s removing jaundice
CN1853506A (en) Health-care food for improving human immunity and production thereof
CN1493678A (en) Health care and nourish life wine and its making method
CN102078512A (en) Pharmaceutical composition for improving fatigue and preparation method thereof
JP2003171303A (en) Composition comprising specific plant, and medicine and food for health use comprising the same composition as active ingredient
Li Chinese herbal medicine
CN102362881A (en) Method for preparing ginkgo and American ginseng preparation
CN1706280A (en) Health food capable of raising immunity and its production process

Legal Events

Date Code Title Description
C06 Publication
C10 Request of examination as to substance
C14 Granted